Atlas Trials

Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer

Clinical trial NCT05812430 · UNKNOWN

Trial details

NCT number
NCT05812430
Sponsor
The First Affiliated Hospital of Zhengzhou University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced Biliary Tract Cancer
Start date
2023-04-10
Primary completion
2023-10-10
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.